1
================================================================================
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
---------------
FORM 8-K
CURRENT REPORT
PURSUANT TO SECTION 13 or 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934
Date of report (Date of earliest event reported): September 14, 1999
------------------------
La Jolla Pharmaceutical Company
- --------------------------------------------------------------------------------
(Exact Name of Registrant as Specified in Charter)
Delaware 0-24274 33-0361285
- --------------------------------------------------------------------------------
(State or Other Jurisdiction (Commission (IRS Employer
of Incorporation) File Number) Identification No.)
6455 Nancy Ridge Drive, San Diego, California 92121
- --------------------------------------------------------------------------------
(Address of Principal Executive Offices) (Zip Code)
Registrant's telephone number, including area code: (858) 452-6600
N/A
- --------------------------------------------------------------------------------
(Former Name or Former Address, if Changed Since Last Report)
================================================================================
2
ITEM 5. OTHER EVENTS
On September 14, 1999, La Jolla Pharmaceutical Company (the "Company")
issued a joint press release with Abbott Laboratories ("Abbott") announcing that
the Company had regained the rights to its experimental lupus drug, LJP 394,
following termination by Abbott of a license and development agreement between
the Company and Abbott. A copy of this press release is attached hereto as
Exhibit 99.1.
On September 14, 1999, the Company issued a press release announcing
that it is restructuring operations while it is evaluating the results of a
clinical trial of its experimental lupus drug, LJP 394. The Company further
announced that its Board of Directors had set a special meeting of stockholders,
the primary purpose of which is to put forth to the stockholders a proposed
one-for-five reverse split of the Company's Common Stock. A copy of this press
release is attached hereto as Exhibit 99.2.
ITEM 7. EXHIBITS
Pursuant to General Instruction F of Form 8-K, the following documents
are incorporated by reference herein and attached as exhibits hereto:
EXHIBIT DESCRIPTION
------- -----------
99.1 La Jolla Pharmaceutical Company and Abbott Laboratories joint
press release of September 14, 1999 regarding the termination
by Abbott Laboratories of the license and development
agreement between La Jolla Pharmaceutical Company and Abbott
Laboratories.
99.2 La Jolla Pharmaceutical Company press release of September 14,
1999 regarding the restructuring of La Jolla Pharmaceutical
Company and the scheduled special meeting of stockholders.
2
3
SIGNATURE
Pursuant to the requirements of the Securities Exchange Act of 1934,
the Registrant has duly caused this current report to be signed on its behalf by
the undersigned hereunto duly authorized.
La Jolla Pharmaceutical Company
Date: September 16, 1999 By: /s/ WOOD C. ERWIN
-----------------------------------
Wood C. Erwin
Chief Financial Officer
3
4
EXHIBIT INDEX
EXHIBIT DESCRIPTION
------- -----------
99.1 La Jolla Pharmaceutical Company and Abbott Laboratories joint
press release of September 14, 1999 regarding the termination
by Abbott Laboratories of the license and development
agreement between La Jolla Pharmaceutical Company and Abbott
Laboratories.
99.2 La Jolla Pharmaceutical Company press release of September 14,
1999 regarding the restructuring of La Jolla Pharmaceutical
Company and the scheduled special meeting of stockholders.
4